The global etomidate market is anticipated to grow at a CAGR of 2.8% during the forecast period (2022-2028). The widespread use of anesthesia for a number of medical procedures has accelerated the global etomidate market. Since etomidate can be utilized as an effective sedative drug, the pharmaceutical sector has been the primary buyer. Conscious sedation is widely used in the medical community, which expands the market’s potential. Etomidate is given to patients with traumatic brain injuries as they aid to maintain arterial pressure by regulating intracranial pressure.
The pace of human metabolism can be accelerated by providing etomidate in controlled doses. As a result, these chemicals are injected into the body to speed up metabolism and the recovery process following surgery.
Some major players in the market include Darmstadt, Pfizer Inc., Emcure Pharmaceuticals Ltd, Merck KGaA, Mylan N.V., Zydus Lifesciences Ltd, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market.
Company’s Product Portfolio
Emcure Pharmaceuticals Ltd offers Etomidate (Amidate) Injection, It’s a nonpyrogenic, sterile fluid. Each milliliter includes 2 mg of etomidate USP and 35 percent v/v propylene glycol. The pH level is 6.0. (4.0 to 7.0). It is used to induce general anesthesia through intravenous injection.
Mylan N.V. offers a generic version of Amidate Injection which got approval from the U.S. Food and Drug Administration. It’s for Etomidate Injection USP, 2 mg/mL, packaged in 40 mg/20 mL single-use vials, according to the Abbreviated New Drug Application (ANDA).
(Get 15% Discount on Buying this Report)
Get Sample Copy of Global Etomidate Marketat https://orionmarketreports.com/request-sample/?id=96751&submit=Request+Sample%0D%0A
Market Coverage
- The market number available for – 2021-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered-
- By Type
- By Application
- Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
- Competitive Landscape- Darmstadt, Pfizer Inc., Emcure Pharmaceuticals Ltd, Merck KGaA, Mylan N.V., Zydus Lifesciences Ltd, among others.
A full report is available at: https://orionmarketreports.com/global-etomidate-market/96751/
Global Etomidate Market Report by Segment
By Application
- Reduction Of Dislocated Joints
- Tracheal Intubation
- Cardioversion and Electroconvulsive Therapy
Key questions addressed by the report
- What is the market growth rate?
- Which segment and region dominate the market in the base year?
- Which segment and region will project the fastest growth in the market?
- How has COVID-19 impacted the market?
- Deviation from the pre-COVID-19 forecast
- Most affected region and segment
- Who is the leader in the market?
- How players are addressing challenges to sustain growth?
- Where is the investment opportunity?
About Us:
Orion Market Reports (OMR) endeavors to provide exclusive blend of qualitative and quantitative market research reports to clients across the globe. Our organization helps both multinational and domestic enterprises to bolster their business by providing in-depth market insights and most reliable future market trends. Our reports address all the major aspects of the markets providing insights and market outlook to global clients.
Media Contact:
Company Name: Orion Market Reports
Contact Person: Mr. Anurag Tiwari
Email: info@orionmarketreports.com
Contact no: +91 780-304-0404
